July 20 Quick Takes: PacBio in $600M takeout of Omniome

Pacific Biosciences of California Inc. (NASDAQ:PACB) is acquiring short-read sequencing company Omniome Inc. for $600 million in cash and stock. Shareholders of the privately held company are eligible to receive another $200 million in milestones. Existing investors in PacBio, which has focused primarily on long-read sequencing, are participating in a $300 million via a PIPE deal to finance the transaction. 

Viking Global Investors led a $135 million series C round for Amylyx Pharmaceuticals Inc., which is developing combination therapy AMX0035 for amyotrophic lateral sclerosis. The Cambridge, Mass.-based company has submitted a regulatory application to Health Canada for the combination of sodium phenylbutyrate and tauroursodeoxycholic acid, and anticipates a submission to EMA by year-end. Data from the CENTAUR trial showed a survival benefit vs. placebo. Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon and Falcon Edge joined existing investors in the round...